425: BioNTech to Acquire CureVac in $1.25 Billion Exchange Offer to Bolster mRNA Capabilities

BioNTech SE announced its planned acquisition of CureVac N.V. through an exchange offer valued at approximately $1.25 billion, aiming to integrate CureVac's mRNA technologies and manufacturing capabilities.

Summary

• BioNTech plans to acquire CureVac N.V. via an exchange offer, a transaction structure common in the pharma/healthcare space, driven by Dutch takeover law.
• Upon closing, CureVac will be delisted from NASDAQ and become a wholly-owned subsidiary of BioNTech.
• The acquisition is subject to customary closing conditions, including regulatory approvals from bodies such as the US FTC and the Antitrust Division of the Department of Justice under the Hart-Scott-Rodino Antitrust Improvements Act.
• Enrolled patients in CureVac's ongoing clinical trials will continue to receive treatments, and CureVac's candidates are expected to be integrated into BioNTech's pipeline.
• CureVac's research and manufacturing site in Tübingen will be integrated into BioNTech's operations until at least the end of 2027.
• CureVac shareholders will receive American Depositary Shares (ADSs) of BioNTech, with each CureVac share exchanged for approximately $5.46 in BioNTech ADSs.
• The implied aggregate equity value for CureVac is approximately $1.25 billion, subject to a collar mechanism: if the 10-day volume weighted average price (VWAP) of BioNTech ADSs exceeds $126.55, the exchange ratio is 0.04318; if the VWAP is lower than $84.37, the exchange ratio is 0.06476.
• CureVac shareholders are expected to own between 4% and 6% of BioNTech post-transaction.
• Shareholders representing 36.76% of CureVac shares, including dievini Hopp BioTech holding GmbH & Co. KG and CureVac's management and supervisory boards, have entered into tender and support agreements.
• The German Federal government, through Kreditanstalt für Wiederaufbau (holding 13.32% of CureVac shares), is expected to support the transaction, bringing total committed support to 50.08% towards the 80% minimum condition required for the exchange offer.

Sentiment

Score: 8

Explanation: The document presents a clear strategic acquisition with strong rationale, significant shareholder support, and detailed plans for integration, indicating a positive outlook for the transaction's success and its potential benefits for BioNTech's strategic goals. The risks mentioned are standard for M&A activities and are not presented as immediate impediments.

Positives

• The acquisition is expected to complement BioNTech's proprietary technologies in mRNA design, delivery formulations, and manufacturing, enhancing its capabilities.
• The transaction structure is designed to align with the interests of both companies' shareholders, support long-term value creation, and maintain BioNTech's financial flexibility.
• BioNTech is committed to ensuring that enrolled patients in CureVac's ongoing clinical trials will continue to receive treatments.
• CureVac's pipeline candidates are expected to be integrated into BioNTech's broader strategic focus, particularly its pan-tumor programs in cancer immunotherapies.
• Significant shareholder support, totaling 50.08% of CureVac shares, has been secured or is expected, moving towards the 80% minimum condition for the exchange offer.

Risks

• Uncertainties exist regarding the precise timing of the exchange offer and the subsequent corporate reorganization of CureVac.
• There is uncertainty as to how many of CureVac's shareholders will tender their shares in the exchange offer.
• The possibility of competing offers or acquisition proposals being made for CureVac could disrupt the current transaction.
• Various conditions to the consummation of the exchange offer and the transactions contemplated by the Purchase Agreement may not be satisfied or waived.
• There is a possibility of a termination of the Purchase Agreement if conditions are not met or other issues arise.
• The ability to obtain necessary regulatory approvals on acceptable terms or within expected timing is not guaranteed.
• The transactions could cause disruption to BioNTech's and/or CureVac's business, impacting relationships with employees, business partners, or governmental entities.
• The exchange offer or other transactions contemplated by the Purchase Agreement may prove to be more expensive to complete than anticipated.
• Litigation in connection with the exchange offer or other transactions could result in significant costs of defense, indemnification, and liability.
• The transaction may lead to a diversion of management's attention from ongoing business operations and opportunities.
• General industry conditions, competition, and broader political, economic, and business conditions (e.g., interest rates, inflation, conflicts) could impact the transaction or future performance.
• Regulatory developments and changes in healthcare legislation in the United States, Europe, and elsewhere, including tax matters, pose risks.
• Challenges and uncertainties inherent in new product development, ability to obtain or maintain intellectual property protection, and issues related to safety, quality, data integrity, or manufacturing could arise.
• Potential or actual data security and data privacy breaches are ongoing risks.

Future Outlook

BioNTech's vision remains focused on improving patient health, with a strategy tailored to execute this mission. The company plans to significantly invest in the broad clinical evaluation of two priority pan-tumor programs across multiple cancer indications, including mRNA cancer immunotherapies. The planned acquisition of CureVac is intended to support this strategy and align with BioNTech's portfolio management, with CureVac's candidates expected to be integrated into BioNTech's pipeline.

Management Comments

• "We believe that the acquisition of CureVac will complement BioNTechs capabilities and proprietary technologies in mRNA design, delivery formulations, and mRNA manufacturing."
• "This transaction structure (exchange offer) is quite common in the pharma/healthcare space. This approach is driven by takeover law in The Netherlands, which is the jurisdiction of organization of CureVac."
• "It is important to both BioNTech and CureVac to ensure that enrolled patients in ongoing clinical trials will continue to receive treatments."
• "BioNTechs vision remains unchanged, and the strategy has been further tailored to execute towards our mission of improving the health of patients in need."
• "BioNTech will develop an integration plan in alignment with its ongoing group-wide transformation, which BioNTech intends to finalize and implement after a successful closing."

Industry Context

This acquisition signifies a strategic move within the rapidly evolving biotechnology and pharmaceutical industries, particularly in the mRNA therapeutic space. It reflects a trend of consolidation where larger players like BioNTech seek to acquire specialized capabilities and pipelines to strengthen their market position, diversify their therapeutic areas, and leverage advanced technologies like mRNA beyond infectious diseases into oncology and other indications. The integration of R&D and manufacturing capabilities is crucial for competitive advantage in this high-growth sector.

Corporate Governance

Legal Proceedings

• Risk that litigation in connection with the exchange offer or the other transactions contemplated by the Purchase Agreement may result in significant costs of defense, indemnification, and liability.

Related Party Transactions

• Certain shareholders of CureVac, including dievini Hopp BioTech holding GmbH & Co. KG and certain of its affiliates, and all members of CureVac's management and supervisory boards, representing 36.76% of CureVac's shares, have entered into tender and support agreements to tender their shares and vote in favor of the transaction.

Stakeholder Impact

• **Shareholders (CureVac)**: Will receive BioNTech ADSs, with an implied value of approximately $5.46 per share, and are expected to collectively own between 4% and 6% of BioNTech post-transaction. Those not tendering will still receive the same consideration via corporate reorganization.
• **Shareholders (BioNTech)**: Expected to benefit from enhanced mRNA capabilities, long-term value creation, and maintained financial flexibility through the acquisition.
• **Employees (CureVac)**: Will be assessed by the same evaluation criteria as part of BioNTech's integration plan, which will comply with relevant legislative frameworks.
• **Patients (CureVac clinical trials)**: BioNTech and CureVac are committed to ensuring that enrolled patients in ongoing clinical trials will continue to receive treatments.
• **Regulatory Bodies**: The transaction requires review and approval from various regulatory bodies, including the US FTC and Department of Justice, ensuring compliance with antitrust and other laws.

Next Steps

• BioNTech intends to file a Registration Statement on Form F-4 with the U.S. Securities and Exchange Commission (SEC), including an offer to exchange/prospectus.
• BioNTech intends to file a Tender Offer Statement on Schedule TO with the SEC.
• CureVac intends to file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC.
• BioNTech will make considerable additional information available in the coming weeks in press releases and SEC filings.
• An extraordinary general meeting of CureVac's shareholders will be convened in connection with the transaction to adopt certain resolutions.
• BioNTech will develop and finalize an integration plan in alignment with its ongoing group-wide transformation after a successful closing.
• BioNTech intends to integrate CureVac's research and manufacturing site in Tübingen until at least the end of 2027.

Key Dates

Recommendation

Keywords

BioNTech, CureVac, acquisition, merger, exchange offer, mRNA technology, biotechnology, pharmaceuticals, clinical trials, NASDAQ delisting, SEC filing, corporate governance, regulatory approval, Germany, United States, American Depositary Shares, tender offer, biopharma